The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The collaboration will center on expanding access to Eastman’s Esmeri technology
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The new functionality complements Parse’s existing Evercode immune products
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
Subscribe To Our Newsletter & Stay Updated
